Recurrence-free survival
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Georgina V Long, Hao Tang, Keyur Desai, Sheen Wang, Michele Del Vecchio, James Larkin, Corey Ritchings, Shu-Pang Huang, Jonathan Baden, David Balli, Han Chang, Gina Fusaro, Daniel Tenney, Sonia Dolfi, Jeffrey Weber
J Immunother Cancer 13(7) e012034
PURPOSE: CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with benefit from adjuvant immunotherapy. PATIENTS AND METHODS: 1,844 patients received nivolumab 480 mg every 4 weeks or nivolumab 240 mg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks. Tumor and peripheral biomarkers were evaluated, including tumor-informed circulating tumor DNA (ctDNA) at postresection baseline and on-treatment, for their association with recurrence-free survival and distant metastases-free survival. RESULTS: Biomarker analyses were conducted in 60-96% of the intention-to-treat population. ctDNA positivity at baseline (seen in 16.2% of patients) and on-treatment was associated with higher risk of recurrence than ctDNA negativity (HR, 1.97; 95% CI, 1.57 to 2.46), with a high specificity (87%) and modest sensitivity (39%). ctDNA status, tumor mutational burden (TMB) status (TMB < or ≥350 mutations/tumor) and interferon gamma-RNA signature score (< or ≥median) evaluated together, as well as ctDNA status with tumor CD8 or cell programmed death ligand 1 expression, were more predictive of survival than ctDNA alone. Tumor bulk RNA-seq expression patterns identified gene expression at baseline associated with recurrence. CONCLUSIONS: This study represents the largest assessment of ctDNA and other baseline tumor and peripheral biomarkers for predicting recurrence-free survival in patients with resected melanoma receiving adjuvant immunotherapy. ctDNA alone and in combination with more established biomarkers predicted recurrence-free and distant metastasis-free survival and has potential utility for assessing and monitoring the risk of recurrence in patients with resected melanoma treated with immunotherapy in the adjuvant setting. TRIAL REGISTRATION NUMBER: NCT03068455.
3 个 Figure · 11 个 KM 面板
Figure 1. Association of baseline ctDNA positivity with ( A ) RFS and ( B ) DMFS; ( C ) Sensitivity and specificity for predicting recurrence; ( D ) Association of baseline ctDNA positivity with first recurrence in the 1,127-patient ctDNA-evaluable subgroup. For recurrences, data from the first recorded 1,138 recurrences in 343 patients in the ctDNA-evaluable cohort with recurrence were used. The pink circles in figures A and B denote early recurrences and highlight the differences in recurrence rates between the baseline ctDNA groups. a In patients with stage III disease. b,c Sensitivity and specificity for predicting RFS and DMFS at 3 and 24 months are represented. To calculate 3-month RFS sensitivity/specificity, the patients with recurrence after ≤3 months were marked as positives and the remaining patients were marked as negatives. The fraction of ctDNA(+) patients among the positives provided the sensitivity of baseline ctDNA and the fraction of ctDNA(−) patients among the negatives provided the specificity of baseline ctDNA in predicting 3-month recurrence. The sensitivity and specificity for RFS at 24 months, DMFS at 3 months, and DMFS at 24 months were determined in a similar manner. ctDNA, circulating tumor DNA; DMFS, distant metastasis-free survival; IPI, ipilimumab; mo, months; NIVO, nivolumab; RFS, recurrence-free survival; ST, soft tissue.
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. ( A ) Landmark analysis of RFS at any time by baseline ctDNA status ( i ) and week 13 ( ii ) and week 29 ( iii ) by on-treatment ctDNA status. ( B ) Association of combined baseline and on-treatment ctDNA status with RFS. BL, baseline; ctDNA, circulating tumor DNA; RFS, recurrence-free survival; W, week.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel A_2
Panel A_2 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel A_3
Panel A_3 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B_5
Panel B_5 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B_6
Panel B_6 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. ( A ) Association of ( i ) ctDNA status, ( ii ) TMB and IFNγ-RNA signature score, and ( iii ) combined ctDNA status, TMB, and IFNγ-RNA signature score with RFS in the pooled nivolumab and nivolumab+ipilimumab treatment arms. ( B ) Time-dependent association of ctDNA status and tumor factors with recurrence in patients treated with nivolumab+ipilimumab. ( i ) Receiver operating characteristic curve for baseline ctDNA status for prediction of recurrence across varying time points. ( ii ) Area under the curve (AUC) for predictive value of ctDNA status over time. ( iii ) AUC for predictive value of individual baseline biomarkers, with each curve representing an individual biomarker and its predictive capacity for RFS with time. ( iv ) AUC for predictive value of baseline biomarker combinations. a IFNγ-RNA signature score: samples were considered high if the signature score was ≥ median. b TMB stratified by tertiles for visualization purposes: TMB low (lower two tertiles), <350 mutations; TMB high (upper tertile), ≥350 mutations. ctDNA, circulating tumor DNA; GEP, gene expression profile; H, high; IFNγ-RNA signature, interferon gamma RNA signature; IHC, immunohistochemistry; L, low; PD-L1, programmed death ligand 1; RFS, recurrence-free survival; t, time; TMB, tumor mutational burden.
Figure 5 · Panel A
Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel A_2
Panel A_2 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel A_3
Panel A_3 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。